Floatz logo

296 assets in Myelodysplastic Syndrome

Therapeutic assets addressing Myelodysplastic Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
cd33 fpbmc
Myelodysplastic Syndrome
University of VirginiaP1C (37)
cd4+cd25+ regulatory t cells
Myelodysplastic Syndrome
Stanford UniversityP1C (37)
Ciml-Nk Cells
Myelodysplastic Syndrome
Dana-Farber Cancer InstituteP1C (37)
Cytokine Induced Memory-Like Natural Killer Cells
Myelodysplastic Syndrome
Dana-Farber Cancer InstituteP1C (37)
Danvatirsen
Myelodysplastic Syndrome
Montefiore Medical CenterP1C (37)
Defactinib
Myelodysplastic Syndrome
Clinical Hub for Interventional Research (CHOIR)P1C (37)
Donor T Cells
Myelodysplastic Syndrome
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsP2C (37)
dsp107
Myelodysplastic Syndrome
Kahr MedicalP1C (37)
Eagd T-Cell Infusion
Myelodysplastic Syndrome
University of Kansas Medical CenterP1C (37)
fxs0683
Myelodysplastic Syndrome
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.P1C (37)
Glb-001
Myelodysplastic Syndrome
Hangzhou GluBio Pharmaceutical Co., Ltd.P1C (37)
Gtb-360
Myelodysplastic Syndrome
Masonic Cancer Center, University of MinnesotaP1C (37)
Immunoglobulin G4, Anti-(Human Cd3 Antigen) (Recombinant Human Monoclonal Jnj-75348780 ?4-Chain), Disulfide With Recombinant Human Monoclonal Jnj-75348780 ? Chain, (229?126?),(232?129?)-Bis(Disulfide) With Immunoglobulin, Anti-(Human Sialic Acid-Binding Ig-Like Lectin 2) (Recombinant Human Single-Domain Vhh Fragment)
Myelodysplastic Syndrome
Janssen Research & Development, LLCP1C (37)
Jnj-54179060
Myelodysplastic Syndrome
Janssen Research & Development, LLCP1C (37)
Jnj-64264681
Myelodysplastic Syndrome
Janssen Research & Development, LLCP1C (37)
Jnj-70218902
Myelodysplastic Syndrome
Janssen Research & Development, LLCP1C (37)
Jnj-80948543
Myelodysplastic Syndrome
Janssen Research & Development, LLCP1C (37)
Jnj-87801493
Myelodysplastic Syndrome
Janssen Research & Development, LLCP1C (37)
lp-108
Myelodysplastic Syndrome
Guangzhou Lupeng Pharmaceutical Company LTD.P1C (37)
mgd024
Myelodysplastic Syndrome
MacroGenicsP1C (37)
Orcagraft
Myelodysplastic Syndrome
Orca Biosystems, Inc.P1C (37)
Prgn-3006 T Cells
Myelodysplastic Syndrome
Precigen, IncP1C (37)
Rem-422
Myelodysplastic Syndrome
Remix TherapeuticsP1C (37)
Sabatolimab
Myelodysplastic Syndrome
Novartis PharmaceuticalsP1/2C (37)
Safimaltib
Myelodysplastic Syndrome
Janssen Research & Development, LLCP1C (37)
sl-172154
Myelodysplastic Syndrome
Shattuck Labs, Inc.P1C (37)
Sprx002
Myelodysplastic Syndrome
Arcellx, Inc.P1C (37)
tqb2928
Myelodysplastic Syndrome
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P1C (37)
Treg-Enriched Donor Cell
Myelodysplastic Syndrome
Dana-Farber Cancer InstituteP1C (37)
trx103
Myelodysplastic Syndrome
Tr1X, Inc.P1C (37)
Tsc-100
Myelodysplastic Syndrome
TScan Therapeutics, Inc.P1C (37)
Tsc-101
Myelodysplastic Syndrome
TScan Therapeutics, Inc.P1C (37)
Vactosertib
Myelodysplastic Syndrome
David WaldP1C (37)
Tagraxofusp-Erzs
Myelodysplastic Syndrome
City of Hope Medical CenterP1D (30)
Autx-703
Myelodysplastic Syndrome
Auron Therapeutics, Inc.P1NR ()
azd3632
Myelodysplastic Syndrome
AstraZenecaP1/2NR ()
bh-30236
Myelodysplastic Syndrome
BlossomHill TherapeuticsP1NR ()
Byon4413
Myelodysplastic Syndrome
Byondis B.V.P1NR ()
gen3018
Myelodysplastic Syndrome
GenmabP1NR ()
lp-118
Myelodysplastic Syndrome
Newave Pharmaceutical IncP1NR ()
nc525
Myelodysplastic Syndrome
NextCure, Inc.P1NR ()
Sgr-2921
Myelodysplastic Syndrome
Schrödinger, Inc.P1NR ()
Showing 251 to 296 of 296 assets
PreviousPage 6 of 6Next